Scott C F, Spitler L E
Clin Exp Immunol. 1983 Jul;53(1):133-9.
Lymphocytotoxic activity has been found by previous investigators in multiple sclerosis (MS) sera. We confirmed the presence of this activity in MS sera using techniques designed to eliminate possible sources of erroneous conclusion not considered in previous studies. We further characterized this activity and found it to be non-dialysable and complement dependent, and, therefore, presumably to be an antibody. This lymphocytotoxic antibody (LCA) is found in those patients with active or progressive disease, and appears to be preferentially directed against the suppressor subset of T cells, as defined by monoclonal antibodies. The LCA may play a role in the pathogenesis of acute exacerbation of MS.
先前的研究人员在多发性硬化症(MS)患者的血清中发现了淋巴细胞毒性活性。我们采用了一些技术来消除先前研究中未考虑到的可能导致错误结论的因素,从而证实了MS患者血清中存在这种活性。我们进一步对这种活性进行了表征,发现它是不可透析的且依赖补体,因此推测它是一种抗体。这种淋巴细胞毒性抗体(LCA)在患有活动性或进行性疾病的患者中被发现,并且似乎优先针对单克隆抗体所定义的T细胞抑制亚群。LCA可能在MS急性加重的发病机制中起作用。